4月8日 - ** 制药商 ANI Pharmaceuticals ANIP.O 股价盘前上涨 7% 至 85.09 美元
** 该公司称，在获得美国 FDA 批准后，它推出了 Monoket 药物的仿制药版本
** 该公司称，该药是单硝酸异山梨酯片剂，有10毫克和20毫克两种剂量，用于预防与心脏病有关的胸痛
** 当心脏得不到足够的血液和氧气时，就会出现胸痛，也称为心绞痛。
** 公司表示，该产品的推出符合 ANI 在竞争有限的市场上销售低成本药物的战略
** ANIP 首席执行官表示，批准和上市突出了该公司为扩大廉价药品的供应所做的努力
** 截至上一交易日收盘，股价年累计上涨 ~1%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.